KOSPI large cap
Hanall Biopharma
A pharma developing antibody drugs for autoimmune and ophthalmic diseases. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
009420.KS Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-45.7%'22-6.3%'23+88.1%'24+32.1%'25+26.4%YTD+11.5%
Money in ▸·
Hanall Biopharma
▸ Money out·
Financials & Segments
- Segments · Prescription drugs · Drug development and royalties
Revenue from
No refined links yet.
Pays to
No refined links yet.